In early July 2022, I learned from the American Association for the Study of Liver Disease (AASLD) that they’ll be updating their PSC Guidance to limit the use of oral vancomycin to clinical trials. Their Guidance will also state that treating IBD associated with PSC is outside their scope. If this AASLD Guidance passes, insurance […]